UBS Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.89M | Sell |
45,174
-24,526
| -35% | -$1.27M | ﹤0.01% | 4748 |
|
|
2026
Q1 | $3.36M | Sell |
69,700
-8,216
| -11% | -$364K | ﹤0.01% | 4474 |
|
|
2025
Q4 | $3.21M | Buy |
77,916
+28,099
| +56% | +$1.13M | ﹤0.01% | 4483 |
|
|
2025
Q3 | $1.93M | Buy |
49,817
+19,201
| +63% | +$624K | ﹤0.01% | 4983 |
|
|
2025
Q2 | $847K | Sell |
30,616
-19,373
| -39% | -$493K | ﹤0.01% | 5587 |
|
|
2025
Q1 | $1.11M | Sell |
49,989
-8,609
| -15% | -$177K | ﹤0.01% | 5193 |
|
|
2024
Q4 | $1.16M | Buy |
58,598
+9,091
| +18% | +$207K | ﹤0.01% | 5194 |
|
|
2024
Q3 | $1.24M | Buy |
+49,507
| New | +$1.21M | ﹤0.01% | 4459 |
|
|
2024
Q2 | – | Sell |
-104,762
| Closed | -$2.07M | – | 9829 |
|
|
2024
Q1 | $2.07M | Buy |
104,762
+19,346
| +23% | +$378K | ﹤0.01% | 3928 |
|
|
2023
Q4 | $1.5M | Buy |
85,416
+22,602
| +36% | +$371K | ﹤0.01% | 4114 |
|
|
2023
Q3 | $1.09M | Buy |
62,814
+18,171
| +41% | +$306K | ﹤0.01% | 3991 |
|
|
2023
Q2 | $629K | Sell |
44,643
-6,672
| -13% | -$89.3K | ﹤0.01% | 4633 |
|
|
2023
Q1 | $552K | Sell |
51,315
-5,790
| -10% | -$76.3K | ﹤0.01% | 4606 |
|
|
2022
Q4 | $855K | Buy |
+57,105
| New | +$831K | ﹤0.01% | 4223 |
|
|
2022
Q2 | – | Sell |
-1,173
| Closed | -$12K | – | 10640 |
|
|
2022
Q1 | $12K | Sell |
1,173
-75,302
| -98% | -$798K | ﹤0.01% | 8187 |
|
|
2021
Q4 | $900K | Sell |
76,475
-6,262
| -8% | -$77K | ﹤0.01% | 4485 |
|
|
2021
Q3 | $942K | Buy |
82,737
+62,718
| +313% | +$817K | ﹤0.01% | 4246 |
|
|
2021
Q2 | $279K | Sell |
20,019
-15,624
| -44% | -$237K | ﹤0.01% | 5130 |
|
|
2021
Q1 | $660K | Buy |
35,643
+34,276
| +2,507% | +$701K | ﹤0.01% | 4640 |
|
|
2020
Q4 | $24K | Sell |
1,367
-1,143
| -46% | -$20.1K | ﹤0.01% | 6805 |
|
|
2020
Q3 | $38K | Sell |
2,510
-8,141
| -76% | -$153K | ﹤0.01% | 5838 |
|
|
2020
Q2 | $271K | Buy |
10,651
+3,441
| +48% | +$71.9K | ﹤0.01% | 4586 |
|
|
2020
Q1 | $112K | Sell |
7,210
-11,758
| -62% | -$184K | ﹤0.01% | 5193 |
|
|
2019
Q4 | $210K | Buy |
18,968
+9,604
| +103% | +$83.5K | ﹤0.01% | 5571 |
|
|
2019
Q3 | $80K | Buy |
9,364
+7,629
| +440% | +$84.3K | ﹤0.01% | 5899 |
|
|
2019
Q2 | $23K | Buy |
+1,735
| New | +$26.9K | ﹤0.01% | 6516 |
|
|
2018
Q4 | – | Sell |
-1,530
| Closed | -$39K | – | 8168 |
|
|
2018
Q3 | $39K | Buy |
+1,530
| New | +$29.8K | ﹤0.01% | 6350 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
UBS Group's KNSA Position: Q2 2026 in Review
UBS Group reduced its Kiniksa Pharmaceuticals (KNSA) stake by 35% in Q2 2026, selling an estimated $1.27M and leaving 45,174 shares worth $2.89M. The position accounts for ﹤0.01% of the portfolio, ranked #4748.
UBS Group first reported a position in KNSA in Q3 2018 and has held it in 27 quarters since. The position peaked at $3.36M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- UBS Group held 45,174 shares of Kiniksa Pharmaceuticals worth $2.89M as of Q2 2026.
- UBS Group sold 24,526 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.27M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4748 holding.
- UBS Group first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
- UBS Group's Kiniksa Pharmaceuticals position peaked at $3.36M in Q1 2026.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.